Tourmaline Bio
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public, Subsidiary
- Established
- 2002-01-01
- Employees
- 44
- Market Cap
- $428.2M
- Website
- http://www.tourmalinebio.com
- Introduction
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.
Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
Phase 1
Completed
- Conditions
- Sickle Cell Disease
- Interventions
- Biological: Enriched Hematopoetic Stem Cell Infusion
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Talaris Therapeutics Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT00777231
- Locations
- ๐บ๐ธ
University of Louisville, Louisville, Kentucky, United States
๐บ๐ธSt. Christopher's Hospital for Children, Pittsburgh, Pennsylvania, United States
๐บ๐ธDuke University Medical Center, Durham, North Carolina, United States
Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion
Phase 1
Active, not recruiting
- Conditions
- Renal Failure
- Interventions
- Biological: Enriched Hematopoietic Stem Cell Infusion
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Talaris Therapeutics Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT00498160
- Locations
- ๐บ๐ธ
Northwestern Memorial Hospital, Chicago, Illinois, United States
๐บ๐ธUniversity of Louisville, Louisville, Kentucky, United States
Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion
Phase 2
Terminated
- Conditions
- Kidney Failure
- Interventions
- Biological: Enriched Hematopoietic Stem Cell Infusion
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Talaris Therapeutics Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00497926
- Locations
- ๐บ๐ธ
Northwestern Memorial Hospital, Chicago, Illinois, United States
๐บ๐ธDuke University, Durham, North Carolina, United States
Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis
Phase 1
Withdrawn
- Conditions
- Multiple Sclerosis
- Interventions
- Biological: hematopoetic stem cell infusion
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Talaris Therapeutics Inc.
- Registration Number
- NCT00497952
ยฉ Copyright 2025. All Rights Reserved by MedPath